Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 148: 112710, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35217280

ABSTRACT

Skin cancer is the most common cancer in the United States and among Caucasians worldwide, with more people diagnosed each year than all other cancers combined. Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually, and treatment costs estimated at $4.8 billion. The objective of this study was to compare efficacy of a topical solution consisting of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in the treatment of basal cell carcinoma. Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod, a standard and well characterized topical treatment. After 8 weeks, post-treatment biopsy of lesions showed complete resolution of 13/15 (86.7%) in the ascorbic acid group, while 8/14 (57.1%) lesions in the IMQ group were resolved (p < 0.05 Chi Square). Topical ascorbic acid was superior at 8 weeks, and non-inferior at 12 weeks to topical imiquimod in the treatment of low risk nodular and superficial lesions. In addition, ascorbic acid was associated with fewer adverse effects than imiquimod. 70% of patients in the imiquinod group showed residual hypopigmentation at 30mo follow up versus 0% in the ascorbate group.


Subject(s)
Antineoplastic Agents , Carcinoma, Basal Cell , Skin Neoplasms , Administration, Topical , Aminoquinolines , Antineoplastic Agents/adverse effects , Ascorbic Acid/adverse effects , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/pathology , Dimethyl Sulfoxide , Humans , Imiquimod/adverse effects , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Treatment Outcome
2.
Biomed Pharmacother ; 58(4): 245-7, 2004 May.
Article in English | MEDLINE | ID: mdl-15183850

ABSTRACT

Molluscum contagiosum is a common viral illness of childhood and is increasingly found as a sexually transmitted disease in sexually active young adults. Current treatment options are invasive, requiring tissue destruction and attendant discomfort. Thirty-one children (mean age 4.6 +/- 2.1 years) with the diagnosis of molluscum contagiosum (mean length of time with condition 8.6 +/- 5.3 months) were treated with once daily topical application of a 10% solution (v/v) of essential oil of Australian lemon myrtle (Backhousia citriodora) or vehicle (olive oil). At the end of 21 days, there was greater than 90% reduction in the number of lesions in 9/16 children treated with lemon myrtle oil, while 0/16 children met the same criteria for improvement in the vehicle group (P < 0.05). No adverse events were reported.


Subject(s)
Molluscum Contagiosum/drug therapy , Myrtaceae/chemistry , Oils, Volatile/pharmacology , Phytotherapy , Administration, Cutaneous , Child, Preschool , Humans , Oils, Volatile/administration & dosage , Oils, Volatile/chemistry , Plant Leaves/chemistry
3.
Biochem Biophys Res Commun ; 303(2): 504-7, 2003 Apr 04.
Article in English | MEDLINE | ID: mdl-12659846

ABSTRACT

Chronic anthracycline administration results in a time- and dose-dependent cardiomyopathy. The Ca-ATPase of the sarcoplasmic reticulum, SERCA2, has been implicated as a principal target for anthracycline-induced cardiotoxicity. This hypothesis predicts that improved SERCA2 function would provide protection from cardiotoxic effects of anthracycline administration. Doxorubicin was administered (1.7 mg/kg three times weekly; cumulative dose of 20 mg/kg) to 10 transgenic mice that overexpressed SERCA2 and to 10 isogenic littermates. Survival was monitored for 60 days and histologic comparisons were made of cardiac tissue. Survival in the transgenic mice was worse (1/10 60-day survivors) compared to isogenic control mice (7/10 60-day survivors). There was a greater degree of histologic damage exhibited in hearts from transgenic mice compared to isogenic controls when all available hearts were examined. These data do not support a role of SERCA2 in ameliorating anthracycline cardiotoxicity.


Subject(s)
Antibiotics, Antineoplastic/toxicity , Calcium-Transporting ATPases/genetics , Doxorubicin/toxicity , Heart/drug effects , Myocardium/pathology , Animals , Calcium-Transporting ATPases/metabolism , Isoenzymes/genetics , Isoenzymes/metabolism , Mice , Mice, Transgenic , Rats , Recombinant Proteins/metabolism , Reference Values , Sarcoplasmic Reticulum Calcium-Transporting ATPases
4.
Biomed Pharmacother ; 56(6): 283-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12224599

ABSTRACT

Approximately 30% of women afflicted with migraine have menstrually associated attacks. These migraines are often refractory to treatment. Evidence suggests estrogen and progestin fluctuations may influence menstrual migraine. Phytoestrogens have demonstrated estrogenic effects in some tissues, but are without stimulation of the endometrium, suggesting decreased risk with long-term use. This study was undertaken to assess the efficacy of a phytoestrogen combination in the prophylactic treatment of menstrual migraine. Forty-nine patients were randomized to receive either placebo, or a daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh, with each component standardized to its primary alkaloid. Patients received study medication for 24 weeks. Average frequency of menstrually associated migraine attacks during weeks 9-24 was reduced from 10.3 +/- 2.4 (mean +/- s.e.m.) in placebo treated patients to 4.7 +/- 1.8 (P < 0.01) in patients treated with the phytoestrogen preparation.


Subject(s)
Estrogens, Non-Steroidal/therapeutic use , Isoflavones , Menstrual Cycle , Migraine Disorders/drug therapy , Phytotherapy/methods , Adolescent , Adult , Angelica sinensis , Cimicifuga , Drug Combinations , Drugs, Chinese Herbal , Female , Humans , Menstrual Cycle/physiology , Middle Aged , Migraine Disorders/etiology , Migraine Disorders/physiopathology , Phytoestrogens , Phytotherapy/statistics & numerical data , Plant Extracts/therapeutic use , Plant Preparations , Glycine max , Statistics, Nonparametric
5.
Biochem Biophys Res Commun ; 291(3): 433-8, 2002 Mar 01.
Article in English | MEDLINE | ID: mdl-11855807

ABSTRACT

Chronic anthracycline administration to rabbits causes impairment of cardiac contractility and decreased gene expression of the calcium-induced calcium release channel of sarcoplasmic reticulum (SR), the ryanodine receptor (RYR2). The C-13 hydroxy metabolite (doxorubicinol), formed in the heart, has been hypothesized to contribute to anthracycline cardiotoxicity. C-13 deoxydoxorubicin is an analog unable to form the C-13 hydroxy metabolite. Therefore, doxorubicin, C-13 deoxydoxorubicin, or saline was administered to rabbits (1 mg/kg iv twice weekly for 8 weeks). Left ventricular fractional shortening (LVFS) was decreased by chronic treatment with doxorubicin (28 +/- 2%; P < 0.05), but not C-13 deoxydoxorubicin (33 +/- 2%) compared to age-matched pair-fed controls. Doxorubicin, but not C-13 deoxydoxorubicin, caused a significant reduction (P < 0.02) in the ratio of RYR2/Ca-Mg ATPase (SERCA2) mRNA levels (0.57 +/- 0.1 vs 1.22 +/- 0.2, respectively) in the left ventricle. This suggests that doxorubicinol may contribute to the downregulation of cardiac RYR2 expression in chronic doxorubicin cardiotoxicity.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Doxorubicin/pharmacology , Ryanodine Receptor Calcium Release Channel/metabolism , Ventricular Dysfunction, Left/metabolism , Animals , Antibiotics, Antineoplastic/chemistry , Calcium-Transporting ATPases/genetics , Calcium-Transporting ATPases/metabolism , Down-Regulation , Doxorubicin/analogs & derivatives , Doxorubicin/chemistry , Male , Myocardial Contraction , RNA, Messenger/biosynthesis , Rabbits , Ryanodine Receptor Calcium Release Channel/genetics , Sarcoplasmic Reticulum/metabolism , Sarcoplasmic Reticulum Calcium-Transporting ATPases , Ventricular Dysfunction, Left/chemically induced , Ventricular Dysfunction, Left/genetics , Ventricular Dysfunction, Left/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...